Chairs
Current Chair: Neha Patel
Chair-elect candidate: Dania Alhamad
BOD Liaison
Laurie Cohen
Charged with keeping the Society informed on topics about both new and existing drugs and devices. To review problems related to the therapeutics of Pediatric Endocrine disorders and report to the Board of Directors and the greater membership of PES.
Levemir®, Discontinued
November 27, 2023
Novo Nordisk announced on 11/8/2023 that their long-acting insulin, Levemir®, will…
New Drugs and Therapeutics Update – NGENLA
November 8, 2023
New Drugs and Therapeutics Update – NGENLA By Dania Al-Hamad,…
Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide)
October 26, 2023
Brief Therapeutic Update from PES Drugs and Therapeutics Committee Jardiance®…